Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have histologically confirmed CD30-positive hematologic malignancy.
Patients with HL must have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy after initial radiotherapy for early stage disease and were ineligible for, refused treatment by, or previously received stem cell transplant.
Patients must have measurable disease of at least 10mm as documented by radiographic technique.
Must be at least 18 years of age.
You may not be if
Patients with current diagnosis of pcALCL (systemic ALCL eligible).
Patients with history of allogeneic stem cell transplant.
Patients who have had previous treatment with any anti-CD30 antibody.
Clareo Health | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
